Kalvista Pharmaceuticals Stock Performance
| KALV Stock | USD 11.44 0.13 1.12% |
The company secures a Beta (Market Risk) of 0.83, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Kalvista Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Kalvista Pharmaceuticals is expected to be smaller as well. Kalvista Pharmaceuticals has an expected return of -0.017%. Please make sure to verify Kalvista Pharmaceuticals information ratio, potential upside, as well as the relationship between the Potential Upside and rate of daily change , to decide if Kalvista Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Kalvista Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable essential indicators, Kalvista Pharmaceuticals is not utilizing all of its potentials. The current stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
Actual Historical Performance (%)
One Day Return 0.17 | Five Day Return (1.78) | Year To Date Return (4.61) | Ten Year Return (85.11) | All Time Return (85.11) |
Last Split Factor 1:14 | Dividend Date 2016-11-22 | Last Split Date 2016-11-22 |
1 | Two Biotechpharma stocks to watch - STTK, KALV | 02/14/2024 |
2 | Exercise or conversion by Christopher Yea of 18788 shares of Kalvista Pharmaceuticals subject to Rule 16b-3 | 02/21/2024 |
3 | KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma Immunology Annual Meetin... | 02/27/2024 |
4 | KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update | 03/11/2024 |
5 | KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine Designation for Sebetralstat | 03/12/2024 |
6 | KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 04/02/2024 |
7 | China Universal Asset Management Co. Ltd. Purchases Shares of 81 KalVista Pharmaceuticals, Inc. - Defense World | 04/08/2024 |
8 | KalVista Pharmaceuticals, Inc. Short Interest Update - MarketBeat | 04/16/2024 |
9 | Disposition of 12083 shares by Audhya Paul K. of Kalvista Pharmaceuticals subject to Rule 16b-3 | 04/17/2024 |
10 | Disposition of 2419 shares by Audhya Paul K. of Kalvista Pharmaceuticals subject to Rule 16b-3 | 04/19/2024 |
| Begin Period Cash Flow | 30.7 M | |
| Total Cashflows From Investing Activities | 41.4 M |
Kalvista |
Kalvista Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,216 in Kalvista Pharmaceuticals on January 24, 2024 and sell it today you would lose (72.00) from holding Kalvista Pharmaceuticals or give up 5.92% of portfolio value over 90 days. Kalvista Pharmaceuticals is currently does not generate positive expected returns and assumes 4.0672% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Kalvista, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Kalvista Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kalvista Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kalvista Pharmaceuticals, and traders can use it to determine the average amount a Kalvista Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0042
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KALV |
Estimated Market Risk
| 4.07 actual daily | 35 65% of assets are more volatile |
Expected Return
| -0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Kalvista Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kalvista Pharmaceuticals by adding Kalvista Pharmaceuticals to a well-diversified portfolio.
Kalvista Pharmaceuticals Fundamentals Growth
Kalvista Stock prices reflect investors' perceptions of the future prospects and financial health of Kalvista Pharmaceuticals, and Kalvista Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kalvista Stock performance.
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.42 | ||||
| Current Valuation | 419.98 M | ||||
| Shares Outstanding | 42.19 M | ||||
| Price To Earning | (2.82) X | ||||
| Price To Book | 5.66 X | ||||
| Price To Sales | 107.42 X | ||||
| Gross Profit | (80.28 M) | ||||
| EBITDA | (110.24 M) | ||||
| Net Income | (92.91 M) | ||||
| Cash And Equivalents | 142.08 M | ||||
| Cash Per Share | 5.78 X | ||||
| Total Debt | 8.23 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 17.51 X | ||||
| Book Value Per Share | 2.56 X | ||||
| Cash Flow From Operations | (75.26 M) | ||||
| Earnings Per Share | (3.12) X | ||||
| Market Capitalization | 488.12 M | ||||
| Total Asset | 183.2 M | ||||
| Retained Earnings | (343.08 M) | ||||
| Working Capital | 157.29 M | ||||
| Current Asset | 54.95 M | ||||
| Current Liabilities | 4.27 M | ||||
About Kalvista Pharmaceuticals Performance
To evaluate Kalvista Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Kalvista Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Kalvista Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Kalvista Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Kalvista's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.2 K | 1.1 K | |
| Return On Tangible Assets | (1.09) | (1.03) | |
| Return On Capital Employed | 18.02 | 18.92 | |
| Return On Assets | (1.09) | (1.03) | |
| Return On Equity | 0.16 | 0.17 |
Things to note about Kalvista Pharmaceuticals performance evaluation
Checking the ongoing alerts about Kalvista Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kalvista Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kalvista Pharmaceuticals generated a negative expected return over the last 90 days | |
| Kalvista Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (92.91 M) with loss before overhead, payroll, taxes, and interest of (80.28 M). | |
| Kalvista Pharmaceuticals currently holds about 142.08 M in cash with (75.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78. | |
| Kalvista Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: KalVista Pharmaceuticals, Inc. Short Interest Update - MarketBeat |
- Analyzing Kalvista Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kalvista Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Kalvista Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kalvista Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kalvista Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kalvista Pharmaceuticals' stock. These opinions can provide insight into Kalvista Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kalvista Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Kalvista Stock analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |
Is Kalvista Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kalvista Pharmaceuticals. If investors know Kalvista will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kalvista Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.12) | Revenue Per Share 0.214 | Quarterly Revenue Growth 0.307 | Return On Assets (0.42) | Return On Equity (0.79) |
The market value of Kalvista Pharmaceuticals is measured differently than its book value, which is the value of Kalvista that is recorded on the company's balance sheet. Investors also form their own opinion of Kalvista Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kalvista Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kalvista Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kalvista Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kalvista Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kalvista Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kalvista Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.